There have been significant economic benefits in Europe since the approval of the first biosimilar more than a decade ago. Although the first FDA biosimilar approval was in 2015, biosimilars are gaining traction in the United States and their success is expected to mirror that in Europe. However, for biosimilars to achieve and maintain a strong position in the major markets, it is imperative for them to attain the trust of physicians; elucidating their decision-making process is therefore, likely to be an important factor in our analysis of biosimilar uptake. Decision Resources Group conducted primary market research in the United States, France, and Germany with physicians across six different specialties to obtain insight into their experiences, attitudes, and perceptions of biosimilars. In this report, we examine how physicians’ experiences and attitudes compare across specialties and countries and how they have evolved over time.
Questions Answered in This Report:
Markets covered: United States, France, and Germany.
Primary research: Online quantitative survey of 550 physicians across six specialties, namely endocrinologists, gastroenterologists, nephrologists, rheumatologists, and hematology and medical oncologists.